Stock CBPL CHANDRA BHAGAT PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Chandra Bhagat Pharma Limited

Equities

CBPL

INE07QQ01016

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:52 2024-05-06 EDT 		5-day change 1st Jan Change
119.4 INR +3.96% Intraday chart for Chandra Bhagat Pharma Limited +3.96% +2.01%
2023 Chandra Bhagat Pharma Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
2023 Chandra Bhagat Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI

Valuation

Fiscal Period: March 2020 2021 2022 2023
Capitalization 1 301.8 298.8 858.6 731.9
Enterprise Value (EV) 1 593.1 541.3 1,011 855.8
P/E ratio 72.7 x 158 x 108 x 80.8 x
Yield - - - -
Capitalization / Revenue 0.32 x 0.42 x 0.91 x 0.61 x
EV / Revenue 0.63 x 0.77 x 1.07 x 0.71 x
EV / EBITDA 18.1 x 13 x 19.6 x 22.7 x
EV / FCF -4.63 x 9.87 x 9.41 x 31.4 x
FCF Yield -21.6% 10.1% 10.6% 3.19%
Price to Book 1.17 x 1.15 x 3.22 x 2.66 x
Nbr of stocks (in thousands) 7,545 7,545 7,545 7,545
Reference price 2 40.00 39.60 113.8 97.00
Announcement Date 20-12-01 21-10-23 22-09-06 23-09-05
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 970.9 1,063 939.8 707 942.1 1,198
EBITDA 1 44.56 45.05 32.69 41.74 51.54 37.76
EBIT 1 43.98 44.53 32.37 41.4 51.17 36.66
Operating Margin 4.53% 4.19% 3.44% 5.86% 5.43% 3.06%
Earnings before Tax (EBT) 1 15.33 8.857 4.224 2.789 11.05 14.11
Net income 1 10.34 6.259 3.148 1.899 7.967 9.054
Net margin 1.06% 0.59% 0.33% 0.27% 0.85% 0.76%
EPS 2 3.090 1.167 0.5500 0.2500 1.056 1.200
Free Cash Flow 1 -52.1 -65.38 -128.1 54.82 107.4 27.27
FCF margin -5.37% -6.15% -13.63% 7.75% 11.4% 2.28%
FCF Conversion (EBITDA) - - - 131.35% 208.33% 72.21%
FCF Conversion (Net income) - - - 2,887.27% 1,347.8% 301.19%
Dividend per Share - - - - - -
Announcement Date 20-01-30 20-01-30 20-12-01 21-10-23 22-09-06 23-09-05
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 201 267 291 242 152 124
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 4.52 x 5.937 x 8.91 x 5.81 x 2.952 x 3.282 x
Free Cash Flow 1 -52.1 -65.4 -128 54.8 107 27.3
ROE (net income / shareholders' equity) 13% 5.49% 1.57% 0.74% 3.03% 3.34%
ROA (Net income/ Total Assets) 4.82% 3.95% 2.57% 3.53% 4.43% 3.44%
Assets 1 214.3 158.5 122.6 53.76 179.7 262.9
Book Value Per Share 2 25.30 26.80 34.00 34.30 35.40 36.40
Cash Flow per Share 2 1.660 0.8900 0.0700 3.210 7.610 8.530
Capex 1 0.16 0.06 0.04 0.2 1 3.69
Capex / Sales 0.02% 0.01% 0% 0.03% 0.11% 0.31%
Announcement Date 20-01-30 20-01-30 20-12-01 21-10-23 22-09-06 23-09-05
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CHANDRA BHAGAT PHARMA LIMITED Stock Chandra Bhagat Pharma Limited
+2.01% 10.78M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CBPL Stock
  4. Financials Chandra Bhagat Pharma Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW